Why NSCLC Is an AI Priority. Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Its profound biological heterogeneity - varying not just between patients but within individual tumors - has made traditional clinical models inadequate for precise diagnosis, staging, and treatment selection. This creates an urgent need for computational tools that can extract meaningful patterns from complex, high-dimensional data.
Multimodal Data as the Foundation. A key insight from this review is that no single data type is sufficient on its own. The most effective AI models integrate clinical and electronic health record data (used in 43.1% of studies), radiomic imaging features (37.5%), and genomic data (19.4%), combining these streams to capture the full biological complexity of each patient's disease.
Deep Learning Leads the Field. Across the studies surveyed, deep learning architectures were the most frequently applied algorithm class, outperforming traditional statistical methods particularly when applied to multimodal inputs. Random forest, support vector machines, logistic regression, and XGBoost also featured prominently, each with particular strengths depending on the clinical task and data type.
Systematic Literature Search. A comprehensive PubMed search identified AI and ML studies published from approximately 2020 to 2025 using keywords spanning machine learning, artificial intelligence, NSCLC, diagnosis, prognosis, genomics, imaging, and risk factors. Studies were organized by data modality and methodological approach.
Three Primary Data Categories. The reviewed studies drew on clinical and electronic health record data, imaging-based radiomics, and genomic profiling. Many studies combined more than one category, with multimodal studies consistently delivering the strongest predictive performance.
Algorithm Landscape. The review catalogued the full range of methods: supervised algorithms (convolutional neural networks, random forest, XGBoost, support vector machines, logistic regression, k-nearest neighbors, Naive Bayes), unsupervised methods (k-means clustering, principal component analysis), and hybrid deep learning architectures (CNNs combined with recurrent units, ensemble models with explainability layers).
CT Imaging Achieves Near-Perfect Accuracy. Several deep learning models achieved striking performance on CT-based cancer detection. A custom CNN with differential image augmentation reached 98.78% accuracy on CT datasets, outperforming established architectures including DenseNet, ResNet, and EfficientNet. An ensemble of VGG16, ResNet50, and InceptionV3 with Grad-CAM explainability achieved 98.18% overall accuracy with near-perfect precision and recall for malignant cases.
Automated Tumor Segmentation Is Ready for Clinical Workflows. A three-stage pipeline including a 2D U-Net for segmentation achieved AUCs of approximately 0.96 internally and 0.98 externally across multiple institutions, with inference times under three seconds per patient. Automated contours were faster, more reproducible, and often preferred over manual segmentation by expert readers - a strong signal of workflow readiness.
Transcriptomics Approaches Near-Perfect Classification. Using RNA sequencing data from TCGA, machine learning models (k-nearest neighbors, random forest, support vector machines) achieved AUC values of 0.984 to 1.000 for distinguishing lung adenocarcinoma from normal tissue across mRNA, miRNA, and lncRNA data types. External validation on independent GEO datasets confirmed that several biomarkers maintained AUCs above 0.96, establishing transcriptomic profiling as a powerful diagnostic tool.
Subtype Morphology Encodes Molecular Identity. A lightweight CNN trained on brightfield images of cancer cell cultures achieved 100% accuracy in classifying KRAS-mutant and EGFR-mutant cell lines by Day 1 of observation, suggesting that early morphological patterns visible in microscopy can encode molecular subtype information - with potential implications for rapid, non-genomic molecular screening.
XGBoost Improves Pathological Staging. In a dual-center study, an XGBoost classifier for pathological staging achieved an internal AUC of 0.913 with 87.5% accuracy, 90.9% sensitivity, and 81.4% specificity, maintaining strong performance (AUC 0.882) on external validation. This substantially exceeds what demographic and clinical variables alone can provide.
Radiomics Enables Surgery Planning. For early-stage lung adenocarcinomas, a seven-feature radiomics signature combined with tumor measurements and classified by XGBoost achieved AUC 0.975 with perfect sensitivity on a held-out test set. The model could distinguish patients suitable for minimally invasive wedge resection from those requiring more extensive surgery - a distinction with major implications for patient morbidity and recovery.
Deep Learning Detects Hidden Nodal Disease. A ResNet18-based deep learning model fusing PET and CT imaging at the feature level (DLNMS) consistently outperformed both human readers and single-modality models for detecting occult nodal metastases, achieving AUROCs of 0.875 to 0.958 across three cohorts including a prospective study of 999 patients. The model's high-risk signature was also linked to adverse genomic and tumor microenvironment patterns.
Combining Metabolic and Structural Imaging. SVM-based radiomics models fusing CT structural data and SPECT metabolic data outperformed either modality alone for distinguishing bone metastases from benign bone lesions, achieving AUCs of 0.939 and 0.925 in training and test sets. Adding clinical variables further improved discrimination, underscoring the value of integrated multimodal approaches for metastasis assessment.
Multi-Omic Models Achieve Strong Survival Prediction. A random survival forest model incorporating nine lactylation-related hub genes identified from TCGA multi-omic clustering achieved AUCs of 0.956, 0.975, and 0.954 for 1-, 3-, and 5-year overall survival in the training set, with external validation confirming meaningful discrimination. High-risk patients identified by this model showed more advanced stage, higher recurrence rates, and differential sensitivity to immunotherapy - directly actionable clinical information.
Post-Surgical Recurrence Prediction. Random forest models trained on 650 surgically resected NSCLC patients achieved accuracy of 0.88 and ROC AUC of 0.89 on validation data for predicting recurrence. An XGBoost-Cox framework incorporating 17 clinicopathologic variables plus 52 perioperative laboratory measures achieved 5-year time-dependent AUCs of 0.890, 0.926, and 0.960 for disease-free, overall, and cancer-specific survival respectively, substantially outperforming TNM stage alone.
Immunotherapy Response Modeling. A 55-gene 1D CNN trained on mutation profiles from 429 advanced NSCLC patients treated with PD-1/PD-L1 blockade achieved AUCs around 0.96 for distinguishing durable clinical benefit from non-benefit across multiple validation cohorts. It outperformed both PD-L1 expression and tumor mutational burden - the current standard predictive biomarkers. An ensemble nomogram combining this CNN with SVM and random forest scores further delineated low-, intermediate-, and high-risk subgroups.
Non-Invasive ALK Fusion Detection. A 3D-ResNet model combining CT features with basic clinical data predicted ALK fusion status in NSCLC patients with AUC 0.85 on internal and external validation. Among patients treated with crizotinib, model-positive patients had significantly longer progression-free survival (16.8 vs 7.5 months) than model-negative cases, validating the tool as a clinically meaningful, non-invasive biomarker screen.
From Research to Regulatory Clearance. A growing number of AI tools have progressed from research to regulatory approval, spanning the full NSCLC care continuum. This translational momentum indicates that AI is moving from academic investigation toward standard clinical deployment, at least for specific applications.
Detection and Surveillance Tools. Qure.ai's qXR-LN and qCT LN Quant are FDA-cleared tools for detecting and quantifying lung nodules from chest X-rays and CT scans, respectively, providing malignancy risk scores and tracking volumetric growth over time. Optellum's Virtual Nodule Clinic holds the distinction of being the first FDA-cleared imaging AI digital biomarker for lung cancer, offering radiomics-based cancer prediction scores for clinical decision-making.
Biopsy, Pathology, and Treatment Selection. Intuitive's Ion platform uses AI-enhanced robotic bronchoscopy navigation to reach peripheral nodules for precise biopsy - a key challenge in lung cancer where tumors are often inaccessible by conventional bronchoscopy. Invenio's NIO Lung Cancer Reveal uses real-time AI evaluation during bronchoscopy to confirm whether biopsy tissue is adequate for diagnosis. Roche's VENTANA TROP2 RxDx Device combines digital pathology AI with a companion diagnostic assay to identify NSCLC patients likely to benefit from a specific targeted therapy.
Small, Single-Center Datasets. The most pervasive limitation across the reviewed studies is reliance on relatively small, single-institution cohorts. These settings inflate performance metrics and reduce confidence that models will generalize to different patient populations, imaging equipment, or clinical workflows. External validation remains absent for a substantial proportion of published models.
The Black Box Problem. Complex deep learning architectures often cannot explain which features or patterns drove a specific prediction. This interpretability gap complicates clinician trust, regulatory assessment, and the ability to detect when a model has learned spurious correlations rather than genuine biology. Tools like Grad-CAM provide partial visual explanations for image-based models, but comprehensive interpretability remains an unsolved problem.
Rare Mutations Are Underserved. Most AI models are trained on common driver mutations (EGFR, ALK) and may fail for patients with rare alterations including NTRK, RET, MET exon 14 skipping, ROS1, BRAF, HER2, and NRG1. These rarer cases are precisely the patients where personalized treatment selection matters most, making this gap clinically significant.
Ethical and Privacy Considerations. Data security, algorithmic bias across demographic groups, and informed consent for AI-based decisions must be systematically addressed before broad deployment. Federated learning - demonstrated by Liu et al. to maintain model performance while keeping patient data at individual institutions - offers one technically promising path to training generalizable models while preserving privacy.
Remarkable Achievements Across the Care Continuum. The evidence synthesized in this review demonstrates that AI and ML have achieved meaningful clinical milestones across NSCLC - near-perfect diagnostic accuracy exceeding 95% in transcriptomic-based classification, robust staging performance with AUC of 0.913, and effective prognosis prediction with AUC of 0.92 across diverse patient populations. These are not marginal improvements over existing methods.
Multimodal Integration Is the Winning Strategy. Consistently across applications, models that integrate data from multiple sources - imaging plus genomics, clinical variables plus radiomics, CT plus molecular profiles - outperform those relying on a single data type. This points toward an architecture for future NSCLC AI systems: comprehensive, patient-specific models that synthesize all available data streams.
The Road to Routine Practice. Translating these achievements into standard care requires prospective multicenter validation studies, improved interpretability tools, standardized data formats across institutions, and thoughtful integration into clinical workflows. The authors advocate for large-scale interdisciplinary collaboration between oncologists, radiologists, genomicists, ethicists, and AI researchers to bridge the gap between research demonstration and durable clinical impact.